Erasca
Erasca
ERAS
NASDAQ
2.89
USD
17.96%
About
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline in the industry, which is focused on modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment.
Its pipeline includes three clinical-stage programs, such as a pan-RAF inhibitor, an ERK inhibitor, and a central nervous system (CNS)-penetrant EGFR inhibitor, and additional discovery-stage programs targeting other key oncogenic drivers. Its lead product candidate is naporafenib, a pan-RAF inhibitor with the potential for patients with NRAS-mutated (NRASm) melanoma, RAS Q61X solid tumors, and other RAS/MAPK pathway-driven tumors..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 1.8M |
| Three Month Average Volume | 42.5M |
| High Low | |
| Fifty-Two Week High | 3.45 USD |
| Fifty-Two Week Low | 1.51 USD |
| Fifty-Two Week High Date | 26 Jul 2024 |
| Fifty-Two Week Low Date | 01 Dec 2023 |
| Price and Volume | |
| Current Price | 2.89 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | 0.02% |
| Thirteen Week Relative Price Change | 7.15% |
| Twenty-Six Week Relative Price Change | 3.07% |
| Fifty-Two Week Relative Price Change | -10.95% |
| Year-to-Date Relative Price Change | 14.58% |
| Price Change | |
| One Day Price Change | 2.85% |
| Thirteen Week Price Change | 14.68% |
| Twenty-Six Week Price Change | 13.33% |
| Five Day Price Change | 5.09% |
| Fifty-Two Week Price Change | 11.58% |
| Year-to-Date Price Change | 35.68% |
| Month-to-Date Price Change | -8.25% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 2.09601 USD |
| Book Value Per Share (Most Recent Quarter) | 1.65209 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 2.09601 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.65209 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.8592 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.83259 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.92066 USD |
| Normalized (Last Fiscal Year) | -0.83259 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.83259 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.92066 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.83259 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.92066 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.06731 USD |
| Cash Per Share (Most Recent Quarter) | 1.4958 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.80774 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.92078 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.66682 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -36.99% |
| EPS Change (Trailing Twelve Months) | 48.50% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 3 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -408,412,000 |
| Net Debt (Last Fiscal Year) | -312,350,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 12 |
| Current Ratio (Most Recent Quarter) | 17 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -102,992,000 |
| Free Cash Flow (Trailing Twelve Months) | -111,719,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -27.48% |
| Return on Assets (Trailing Twelve Months) | -32.76% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -34.33% |
| Return on Equity (Trailing Twelve Months) | -38.90% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -29.94% |
| Return on Investment (Trailing Twelve Months) | -34.48% |
| Return on Investment (5 Year) | -99,999.99% |